{"id":993495,"date":"2026-05-30T02:55:28","date_gmt":"2026-05-30T02:55:28","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/993495\/"},"modified":"2026-05-30T02:55:28","modified_gmt":"2026-05-30T02:55:28","slug":"asco-news-bristol-and-pfizer-report-favorable-results-day-1","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/993495\/","title":{"rendered":"ASCO News: Bristol and Pfizer report favorable results \u2014 Day 1"},"content":{"rendered":"

\t\t\t\t\t\t\t\t\t\t\t\"\"<\/p>\n

\t\t\t\tChicago, where thousands in the cancer world gather each year.Adam Feuerstein\/STAT<\/p>\n

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud<\/a> and author of the newsletter Adam\u2019s Biotech Scorecard.<\/a> You can reach Adam on Signal at stataf.54.<\/p>\n

Matthew Herper covers medical innovation \u2014 both its promise and its perils.<\/p>\n

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.<\/p>\n

You\u2019re reading the web edition of ASCO in 30 Seconds, STAT\u2019s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here<\/a>.\u00a0\u00a0<\/p>\n

We\u2019re ASCOmaxxing.<\/p>\n

Rest assured, this will not require Adam Feuerstein, Matthew Herper or Angus Chen to hammer on their jawlines. They will, however, be scouring the ASCO annual meeting to bring you the cancer news, analysis and event coverage you crave.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n

    \n
  1. \n

    \t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/p>\n

    Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud<\/a> and author of the newsletter Adam\u2019s Biotech Scorecard.<\/a> You can reach Adam on Signal at stataf.54.<\/p>\n<\/li>\n

  2. \n

    \t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/p>\n

    Senior Writer, Medicine, Editorial Director of Events<\/p>\n

      \n
    1. <\/li>\n
    2. <\/li>\n<\/ol>\n

      Matthew Herper covers medical innovation \u2014 both its promise and its perils.<\/p>\n<\/li>\n

    3. \n

      \t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/p>\n

      Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.<\/p>\n<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"Chicago, where thousands in the cancer world gather each year.Adam Feuerstein\/STAT Adam Feuerstein is a senior writer and…\n","protected":false},"author":2,"featured_media":993496,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[8818],"tags":[274366,12848,381,748,1204,5885,393,2460,4884,5489,31173,16,15],"class_list":["post-993495","post","type-post","status-publish","format-standard","has-post-thumbnail","category-bristol","tag-asco","tag-biotechnology","tag-bristol","tag-britain","tag-cancer","tag-drug-development","tag-england","tag-fda","tag-great-britain","tag-pharmaceuticals","tag-stat","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116661278875574934","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/993495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=993495"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/993495\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/993496"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=993495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=993495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=993495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}